All In MedTech

Device Trial Radar · NCT00638235

Pelvic Floor Repair Systems for Prolapse Repair

A Prospective, Multi-Center Study to Assess the AMS Pelvic Floor Repair System Devices for Prolapse Repair

Last checked: Nov 19, 2026Latest source record: Oct 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

725

Actual

Start

May 2006

Primary completion

Feb 2011

Study completion Sep 2012

Sponsor

Lead sponsor
ASTORA Women's HealthNot on our public-company list
Sponsor type
Industry
First posted
Mar 19, 2008

More device trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. This is a prospective, multi-center, post market study, which will be conducted under a common protocol. 2. The primary objective of the study is to evaluate long-term efficacy of the AMS Pelvic Floor Repair System devices for prolapse repair. 3. The study population is female subjects \> 21 years of age who require surgical reconstruction of their pelvic floor due to prolapse. 4. The clinical data will be analyzed by comparing post-treatment data with the baseline data, with the subject acting as her own control. The follow-up is for two years after the procedure. 5. Prolapse improvement measured by ICS POP-Q Stage at 12-months will be the primary endpoint of the study. The secondary endpoints include quality of life changes from baseline and adverse event rates.

Conditions

  • Pelvic Organ Prolapse

Interventions

  • AMS Apogee™ with InteProDevice

    Mesh implant for posterior wall pelvic organ prolapse

  • AMS Apogee™ with Intexen LPDevice

    Graft implant for posterior wall pelvic organ prolapse

  • AMS Perigee™ with InteProDevice

    Mesh implant for anterior wall pelvic organ prolapse

  • AMS Perigee™ with IntePro LiteDevice

    Mesh implant for anterior wall pelvic organ prolapse

  • AMS Apogee™ with IntePro LiteDevice

    Mesh implant for posterior wall pelvic organ prolapse

  • AMS Elevate™ Apical & Posteiror with IntePro LiteDevice

    Mesh implant for apical and posterior wall pelvic organ prolapse

  • AMS Elevate™ Apical & Posteiror with IntXen LPDevice

    Graft implant for apical and posterior wall pelvic organ prolapse

  • AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)Device

    Mesh implant for anteiror and apical wall pelvic organ prolapse

  • AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)Device

    Mesh implant for anteiror and apical wall pelvic organ prolapse

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects With an ICS (International Incontinence Society) POP-Q (Pelvic Organ Prolapse Quantification System) Stage of </= Stage I in the Posterior Compartment at One Year Post ProcedureTime frame: 12-months
  2. Percent of Subjects With an ICS POP-Q Stage of </= Stage I in the Apical Compartment at One Year Post ProcedureTime frame: 12-months
  3. Percent of Subjects With an ICS POP-Q Stage of </= Stage I in the Anterior Compartment at One Year Post ProcedureTime frame: 12-months

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente - Dept. of Obstetrics & Gynecology

    Downey, California

  • Institute for Women's Health & Body

    Wellington, Florida

  • Atlanta Medical Research Institute

    Alpharetta, Georgia

25 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.